ASSOCIATION BETWEEN SPECIFIC CHROMOSOME ABNORMALITIES AND GESTATIONAL AGE AND STAGE OF SPONTANEOUS ABORTIONS


Title:
ASSOCIATION BETWEEN SPECIFIC CHROMOSOME ABNORMALITIES AND GESTATIONAL AGE AND STAGE OF SPONTANEOUS ABORTIONS

Submitter's E-mail Address:
Rebecca.zhuo@mountsinai.org

Preferred Presentation Type:
Oral or Poster

Study Type:
Retrospective Cohort Study (includes comparator groups)

Category - Subcategory(ies):
Genetics: Genetics General

* Submission of an abstract for consideration for presentation implies that the presenting author & associated co-authors have legal and ethical rights to submit and present this work. Plagiarism and submitting work that an author has no rights to, will result in an investigation and penalty.

* I verify that I am in compliance with HIPAA standards to protect the privacy of the patients discussed in my presentation(s). I either have received written authorization from the patient, have removed any identifiable images or patient records from my presentation, or my presentation does not pertain to patient treatment.

Permissions - Prior Publication or Presentation
This abstract contains original work, not published or presented previously at a meeting of another national or international scientific organization prior to this meeting and has not been submitted for publication at the time of this submission.

ACCME Disclosure
Nothing to disclose. No off-label or otherwise non-approved product use.

Did this abstract require approval by a local Institutional Review Board (IRB) or equivalent?
This abstract has been approved by a local Institutional Review Board (IRB) or equivalent.

Applying for an award
Trainee: Yes

Abstract Category:
All Other Categories

Applied for the Resident In-Training Award
Applied for the In-Training Award for Research

Abstract Text:
OBJECTIVE: While studies have identified common chromosomal errors in spontaneous abortions (SABs), it has not been determined whether there is an association between specific chromosomal abnormalities and duration and stage of pregnancy. Therefore, this study aimed to determine whether certain chromosomal abnormalities are associated with gestational age and stage at which SABs occur.
MATERIALS AND METHODS: This single center, retrospective study included first-trimester SABs with cytogenetics report of an abnormal karyotype from 2002-2022. All patients that underwent an intrauterine insemination (IUI) or transfer with an unscreened embryo, and well dated based on IUI or transfer date and by first trimester ultrasound, were included in the study. Patients were stratified into four groups by furthest stage of development prior to the SAB: gestational sac (GS), yolk sac (YS), fetal pole (FP), and fetal heartbeat (FHB). Patients were also divided by gestational age in weeks at the time of SAB. Our primary outcome was chromosomal abnormalities by stage of development. Secondary outcomes included chromosomal abnormalities by gestational age. Comparative statistics were performed using chi-square and Kruskal-Wallis.

RESULTS: A total of 161 SABs were included in the analysis; of these, 133 had trisomies (83%), 5 triploidy (3%), 10 tetraploidies (6%), and 13 monosomies (8%). Trisomies involving chromosomes 15, 16, and 22 were more prevalent in advanced weeks of gestation, while those involving chromosomes 10 and 11 were increased in early pregnancies. Most SABs with chromosomal abnormalities were observed after FHB was identified (73.3%) with the highest incidence at weeks 7 and 8 of gestation (71%). Most of the trisomic losses occurred after FHB (77.4%), and 21.8% reached 9 to 11 weeks of gestation. All losses with triploidy occurred after FHB, with 40% reaching 9 to 11 weeks of gestation. All cases with monosomy progressed until weeks 7 to 11 of gestation. No embryos with tetraploidy progressed to the FHB stage or surpassed 8 weeks of gestation. (Table 1)

CONCLUSIONS: There is an association between the type of chromosomal abnormality and gestational stage of development. While many embryos with trisomy or triploidy go on to develop a FHB, none of the tetraploid embryos reached fetal heart stage.

IMPACT STATEMENT: Specificity in chromosomal abnormalities associates with the stage and age of pregnancy development.

Table 1

| Rate of chromosomal abnormalities by stage of development and gestational age |
|------------------|-------|-----|------|------|------|------|------|
|                  | GS    | YS  | FP   | FHB  | Weeks 5-6 | Weeks 7-8 | Weeks 9-11 |
|                  | (2.5%)| (8.7%)| (15.5%)| (73.3%)| (7%) | (71%) | (22%) |
| Trisomies (83%)  | 4     | 7   | 19   | 103  | 9    | 95   | 29    |
| Monosomies (8%)  | 0     | 2   | 1    | 10   | 0    | 9    | 4     |
| Triploidy (3%)   | 0     | 0   | 0    | 5    | 1    | 2    | 2     |
| Tetraploidy (6%) | 0     | 5   | 5    | 0    | 1    | 9    | 0     |
| p-value          | p=<.0001 | p=0.03 | p=0.002 | p<.0002 | p<.0001 | p<.00001 | p<.0001 |

First Presenting Author

Presenting Author

Rebecca Zhuo, M.D.
Email: Rebecca.zhuo@mountsinai.org -- Will not be published

Icahn School of Medicine at Mount Sinai
Obstetrics, Gynecology, and Reproductive Science
1176 Fifth Ave, Klingenstein Pavilion
New York NY 10029
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Rebecca Zhuo
CV Upload:

- Rebecca Zhuo CV.pdf

Second Author

Tamar Alkon-Meadows, M.D.
Email: talkon@rmany.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Ave 10th Fl
New York NY 10022-1009
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Tamar Alkon -M
- 2022-02-15 19:09:44

CV Upload:

- Tamar Alkon CV 3.docx

Third Author

Atoosa Ghofranian, M.D.
Email: atoosagmd@gmail.com -- Will not be published

Icahn School of Medicine at Mount Sinai
Obstetrics, Gynecology, and Reproductive Science
Klingenstein Pavilion - 1176 Fifth Ave.
New York NY 10029
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Atoosa Ghofranian
- 2022-02-15 19:09:44

CV Upload:

- CV 2021.pdf

Fourth Author

Morgan Baird, MPH
Email: mbaird@rmaofny.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Ave 10th Fl
Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Morgan Baird
- 2022-02-15 19:09:44

Fifth Author

Dmitry Gounko, B.S., M.A.
Email: dgounko@rmaofny.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Ave 10th Fl
New York NY 10022-1009
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Dmitry Gounko
- 2022-02-15 19:09:44

Sixth Author

Joseph Lee, BA
Email: jlee@rmaofny.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Ave 10th Fl
New York NY 10022-1009
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Joseph Adam Lee
- 2022-02-15 19:09:44
CV Upload:

Joseph Lee CV.doc

Seventh Author

Alan B Copperman, M.D.
Email: acopperman@rmany.com -- Will not be published

Reproductive Medicine Associates of New York LLP
635 Madison Ave 10th Fl
New York NY 10022-1009
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
Yes - disclosing all COI

<table>
<thead>
<tr>
<th>Organization Name</th>
<th>Relationship Type</th>
<th>Who has this Relationship?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Progyny</td>
<td>Company Officer Relationship Began - Friday, August 25, 2017</td>
<td>Self</td>
</tr>
<tr>
<td></td>
<td>Relationship Ended - Friday, August 25, 2017</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Direct Stockholder Relationship Began - Friday, August 25, 2017</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Relationship Ended -</td>
<td></td>
</tr>
</tbody>
</table>

Signature: Alan B Copperman
- 2022-02-15 19:09:44

Eighth Author

Erkan Buyuk, M.D.
Email: ebuyuk@rmaofny.com -- Will not be published
Reproductive Medicine Associates of New York  
635 Madison Ave Fl 10  
New York NY 10022-1009  
USA  

Within the past 2 years, have you or your spouse/partner had any potential COI?  
No - disclosing all COI  
Signature: Erkan Buyuk, M.D.  
- 2022-02-15 19:09:44  

If necessary, you can make changes to your abstract submission until Thursday, April 27, 2023 at 5:00 pm (EDT).  
To access your submission in the future, use the link to your user portal from one of the automatic confirmation emails that were sent to you during the submission.  
Or point your browser to https://asrm.confex.com/asrm/2023/gateway.cgi  
You will be prompted to login with your ASRM account prior to accessing the user portal. If you do not yet have an ASRM account, the screen will redirect you to the site where you can register for a new account. When registering for a new ASRM account:  
- Please use the email address that is associated with the submission and your first and last name as they appear on the submission when creating this account.  
- An ASRM account for login must be completed before you can access the user portal.  

Any changes that you make will be reflected instantly in what is seen by the reviewers. You DO NOT need to go through all of the submission steps in order to change one thing. If you want to change the title, for example, just click "Title" in the abstract control panel and submit the new title.  

When you have completed your submission, you may close this browser window.  
If you would like to submit another abstract, click here.  

Tell us what you think of the abstract submission process  
Home Page